BR112015018438A2 - anticorpo contra c5 e método para prevenir e tratar doenças relacionadas a complemento - Google Patents

anticorpo contra c5 e método para prevenir e tratar doenças relacionadas a complemento

Info

Publication number
BR112015018438A2
BR112015018438A2 BR112015018438A BR112015018438A BR112015018438A2 BR 112015018438 A2 BR112015018438 A2 BR 112015018438A2 BR 112015018438 A BR112015018438 A BR 112015018438A BR 112015018438 A BR112015018438 A BR 112015018438A BR 112015018438 A2 BR112015018438 A2 BR 112015018438A2
Authority
BR
Brazil
Prior art keywords
antibody
preventing
related diseases
complement
treating complement
Prior art date
Application number
BR112015018438A
Other languages
English (en)
Inventor
Kyoung Lee Hwa
Kim Hyori
Chung Junho
Jun Yang Won
Original Assignee
Seoul Nat Univ R&Db Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seoul Nat Univ R&Db Foundation filed Critical Seoul Nat Univ R&Db Foundation
Publication of BR112015018438A2 publication Critical patent/BR112015018438A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Abstract

resumo patente de invenção: "anticorpo contra c5 e método para prevenir e tratar doenças relacionadas a complemento". a presente invenção refere-se a um anticorpo contra c5 e um método para prevenir e tratar distúrbios relacionados a complemento com o uso do anticorpo. o anticorpo contra c5 da presente invenção pode ser usado de forma vantajosa na prevenção e no tratamento de distúrbios relacionados a complemento suprimindo-se a ativação de complemento.
BR112015018438A 2013-01-31 2014-02-03 anticorpo contra c5 e método para prevenir e tratar doenças relacionadas a complemento BR112015018438A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361759015P 2013-01-31 2013-01-31
US201361862248P 2013-08-05 2013-08-05
PCT/KR2014/000920 WO2014119969A1 (ko) 2013-01-31 2014-02-03 보체 관련 질환의 예방 및 치료를 위한 c5 항체 및 방법

Publications (1)

Publication Number Publication Date
BR112015018438A2 true BR112015018438A2 (pt) 2017-07-18

Family

ID=51262613

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015018438A BR112015018438A2 (pt) 2013-01-31 2014-02-03 anticorpo contra c5 e método para prevenir e tratar doenças relacionadas a complemento

Country Status (10)

Country Link
US (2) US10280215B2 (pt)
EP (1) EP2975055A4 (pt)
JP (2) JP6608702B2 (pt)
KR (1) KR101638931B1 (pt)
CN (1) CN105143261B (pt)
AU (2) AU2014213147B2 (pt)
BR (1) BR112015018438A2 (pt)
CA (1) CA2899589C (pt)
RU (2) RU2663349C2 (pt)
WO (1) WO2014119969A1 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3056568B1 (en) 2006-03-31 2021-09-15 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
CN106519025B (zh) 2007-09-26 2021-04-23 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
CA2721052C (en) 2008-04-11 2023-02-21 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
TWI654203B (zh) 2010-11-30 2019-03-21 中外製藥股份有限公司 具有鈣依存性的抗原結合能力之抗體
TW201326209A (zh) 2011-09-30 2013-07-01 Chugai Pharmaceutical Co Ltd 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
US10280215B2 (en) * 2013-01-31 2019-05-07 Seoul National University R&Db Foundation Anti-C5 antibodies and methods of treating complement-related diseases
AU2015365167B2 (en) 2014-12-19 2021-07-29 Chugai Seiyaku Kabushiki Kaisha Anti-C5 antibodies and methods of use
SG10201909180SA (en) 2015-04-06 2019-11-28 Bioverativ Usa Inc Humanized anti-c1s antibodies and methods of use thereof
PE20240365A1 (es) * 2015-12-18 2024-03-04 Chugai Pharmaceutical Co Ltd Anticuerpos anti-c5 y metodos de uso
WO2017164678A2 (ko) * 2016-03-23 2017-09-28 서울대학교산학협력단 중증열성혈소판감소증후군 바이러스의 외막 당단백질에 결합하는 항체 및 이의 용도
US20190225678A1 (en) * 2016-06-07 2019-07-25 Novartis Ag Anti-c5 antibody for treating patients with complement c5 polymorphism
KR102534895B1 (ko) 2016-06-14 2023-05-24 리제너론 파아마슈티컬스, 인크. 항-c5 항체 및 이의 용도
KR101852739B1 (ko) * 2016-06-17 2018-04-30 추가이 세이야쿠 가부시키가이샤 항-c5 항체 및 사용 방법
KR20230079499A (ko) 2016-08-05 2023-06-07 추가이 세이야쿠 가부시키가이샤 Il-8 관련 질환의 치료용 또는 예방용 조성물
BR112019007309A2 (pt) * 2016-10-12 2019-07-02 Bioverativ Usa Inc anticorpos anti-c1s e métodos de uso dos mesmos
MX2019010574A (es) * 2017-03-06 2020-01-15 Univ Pennsylvania Anticuerpos anti-c5 y su uso.
US11365265B2 (en) 2017-12-13 2022-06-21 Regeneron Pharmaceuticals, Inc. Anti-C5 antibody combinations and uses thereof
CN112512563A (zh) * 2018-08-01 2021-03-16 中外制药株式会社 用于治疗或预防c5相关疾病的药物组合物和治疗或预防c5相关疾病的方法
CN111234016B (zh) * 2020-02-23 2021-09-07 北京康普美特创新医药科技有限责任公司 一种抗补体c5分子的全人源单克隆抗体及应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6074642A (en) * 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5853975A (en) * 1994-08-23 1998-12-29 Millennium Pharmaceuticals, Inc. Methods for identifying compositions for the treatment of body weight disorders, including obesity
DK1325033T3 (da) * 2000-10-10 2010-04-06 Genentech Inc Inhibering af komplement C5 aktivering til behandlingen og forebyggelsen af forsinket xenograf- eller akut vaskulær afstødning
US20040185040A1 (en) * 2001-11-21 2004-09-23 Celltech R & D Limited Modulating immune responses
UA99591C2 (ru) * 2005-11-04 2012-09-10 Дженентек, Инк. Применение ингибиторов пути комплемента для лечения глазных болезней
CN104623692A (zh) * 2006-03-08 2015-05-20 阿切埃米克斯股份有限公司 治疗视觉失调中使用的补体结合适体和抗-c5药物
US7776573B2 (en) * 2006-06-01 2010-08-17 Genentech, Inc. Crystal structure of CRIg and C3b:CRIg complex
CA2680760A1 (en) * 2007-03-22 2008-09-25 Novartis Ag C5 antigens and uses thereof
EP2666787B1 (en) 2007-05-31 2022-02-09 Genmab A/S STABLE IgG4 ANTIBODIES
WO2008153963A1 (en) * 2007-06-08 2008-12-18 The Trustees Of The University Of Pennsylvania Structure of compstatin-c3 complex and use for rational drug design
HUE026179T2 (en) * 2008-08-05 2016-05-30 Novartis Ag Preparations and methods for antibodies against complement C5 protein
PL2894165T3 (pl) * 2008-11-10 2023-04-17 Alexion Pharmaceuticals, Inc. Sposoby i kompozycje do leczenia zaburzeń układu dopełniacza
SG183541A1 (en) * 2010-03-01 2012-10-30 Alexion Pharma Inc Methods and compositions for treating degos' disease
TW201241008A (en) * 2010-10-01 2012-10-16 Alexion Pharma Inc Polypeptides that bind to human complement component C5
US20140370012A1 (en) * 2012-01-27 2014-12-18 Gliknik Inc. Fusion proteins comprising igg2 hinge domains
US10280215B2 (en) 2013-01-31 2019-05-07 Seoul National University R&Db Foundation Anti-C5 antibodies and methods of treating complement-related diseases

Also Published As

Publication number Publication date
EP2975055A4 (en) 2016-11-02
US20190382472A1 (en) 2019-12-19
CA2899589A1 (en) 2014-08-07
AU2014213147A1 (en) 2015-08-20
RU2663349C2 (ru) 2018-08-03
JP7019198B2 (ja) 2022-02-15
AU2019202606A1 (en) 2019-05-02
US10280215B2 (en) 2019-05-07
RU2015136078A (ru) 2017-03-07
US20160068592A1 (en) 2016-03-10
RU2018125515A (ru) 2018-10-29
RU2018125515A3 (pt) 2021-11-19
JP2020031650A (ja) 2020-03-05
US11339210B2 (en) 2022-05-24
CA2899589C (en) 2022-02-22
WO2014119969A1 (ko) 2014-08-07
AU2019202606B2 (en) 2021-04-15
EP2975055A1 (en) 2016-01-20
CN105143261B (zh) 2021-04-09
KR101638931B1 (ko) 2016-07-12
JP2016513088A (ja) 2016-05-12
AU2014213147B2 (en) 2019-01-17
JP6608702B2 (ja) 2019-11-20
CN105143261A (zh) 2015-12-09
KR20150035354A (ko) 2015-04-06

Similar Documents

Publication Publication Date Title
BR112015018438A2 (pt) anticorpo contra c5 e método para prevenir e tratar doenças relacionadas a complemento
CY1124307T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων
BR112016000546A2 (pt) métodos para tratar ou prevenir condições oftalmológicas
BR112015001847A2 (pt) composições e tratamento para doenças e distúrbios nos olhos
CL2015002485A1 (es) Uso de agonistas de receptor de péptido formilo 2 para tratar enfermedades inflamatorias oculares
BR112015029686A2 (pt) composições para o tratamento de superfícies compreendendo corantes fotocrômicos
CL2018000222A1 (es) Nueva combinación para el uso en el tratamiento del cáncer
BR112016013109A2 (pt) anticorpos de anti-siglec-8 e métodos de seu uso
BR112015025709A2 (pt) monoterapia com gla para uso em tratamento de câncer
BR112015023725A2 (pt) composição de dosagem de filme autossuportante, composição de dosagem de filme, método de tratamento, e, processo de formação de composição de dosagem de filme
BR112014018471A2 (pt) anticorpos anti-ige m1' e métodos para o seu uso
MX2019001977A (es) Metodos y composiciones para tratar esclerosis multiple y trastornos relacionados.
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
BR112015010039A2 (pt) tratamento de câncer com pomalidomida em um individuo com disfunção renal
BR112017007025A2 (pt) sulfatos de colesterol oxigenados para terapia de distúrbios causados por pelo menos um de atividade de leptina atenuada e um distúrbio de armazenamento de lipídio
MX2016000294A (es) Composicion farmaceutica para liberacion sostenida de lanreotida.
MX2016000220A (es) Regulacion del metabolismo de glucosa usando anticuerpos anti-cgrp.
CL2015002181A1 (es) Tratamiento de formas progresivas de esclerosis múltiple con laquinimod.
BR112018069682A2 (pt) métodos de tratamento para doenças colestáticas e fibróticas
BR112014011481A2 (pt) hidrolisado de colágeno e seu uso
BR112015001859A2 (pt) tratamento de inflamação utilizando serelaxina
MX2016003293A (es) Metodos y composiciones para el tratamiento de una infeccion por clamidia y enfermedades y trastornos relacionados.
BR112015004469A2 (pt) sirna e seu uso em métodos e composições para o tratamento e/ou prevenção de condições oculares
BR112014014802A2 (pt) composto, composição farmacêutica, uso de um composto, métodos para tratamento ou para alívio de uma doença ou de um distúrbio ou de uma condição, e para tratamento ou melhora de doenças ou de condições
BR112016016098A2 (pt) Compostos orgânicos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B25A Requested transfer of rights approved

Owner name: IMMUNABS INC. (KR)